Propanc Biopharma, Inc. (NASDAQ: PPCB) is a clinical-stage company that develops new cancer treatments. On May 18, 2026, Propanc Biopharma, Inc. executed a 25-for-1 reverse stock split. This action aims to support its continued listing on the Nasdaq exchange and help with its future growth plans.
A reverse stock split is a corporate action where a company reduces its total number of outstanding shares. This process increases the price per share. For Propanc Biopharma, Inc., every 25 existing shares were combined into one new share of common stock, as highlighted by GlobeNewswire.
This split reduces the number of Propanc Biopharma, Inc.'s outstanding common shares from approximately 57 million to about 2.3 million. Companies often use this strategy to raise their stock price. This helps them meet the minimum price required to stay listed on major exchanges like Nasdaq.
Following the split, Propanc Biopharma, Inc. is trading at a stock price of $2.02, an increase of $0.32 or 18.53% for the day. The stock's trading range for the day is between a low of $1.56 and a high of $2.29. The trading volume is over 236,717 shares.
The stock shows significant price movement, with a 52-week high of $270.25 and a low of $1.56. Propanc Biopharma, Inc. currently has a market capitalization of approximately $1.81 million. Market capitalization is the total market value of a company's outstanding shares of stock.
